Toxicity of post-exposure prophylaxis for human immunodeficiency virus

Bailliere's Clinical Infectious Diseases

Volumn 5, Issue 3, 1998, Pages 349-363

  Wang, S A ^a   Puro, V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Anti retroviral drug side effects; Anti retroviral drug toxicity; Human immunodeficiency virus post exposure prophylaxis

Indexed keywords

ABACAVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ANALGESIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HYPNOTIC AGENT; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SEDATIVE AGENT; STAVUDINE; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTHRALGIA; CHEMOPROPHYLAXIS; DRUG METABOLISM; DRUG SAFETY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MYALGIA; NAUSEA; NEPHROTOXICITY; OCCUPATIONAL EXPOSURE; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION; VOMITING;

EID: 0032228682     PISSN: 10716564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. New drugs for HIV infection
2. Antiretroviral Pregnancy Registry for didanosine (VIDEX®, ddI), lamivudine (EPIVIR(TM), 3tc), saquinavir (INVIRASE®, SAQ), stavudine (ZERIT®, d4T), zalcitabine (HIVID®, ddC), zidovudine (RETROVIR®, ZDV)
3. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine
4. Nonclinical toxicology studies with zidovudine: Genetic toxicity test and carcinogenicity bioassays in mice and rats
5. Combination post-exposure prophylaxis (PEP): A prospective study of HIV-exposed health care workers (HCW)
6. Zidovudine-lamivudine for prevention of mother to child H1V-1 transmission
7. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
8. Birth outcomes following zidovudine therapy in pregnant women
9. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV
10. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis
11. Public Health Service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States
12. Evaluation for the late effects of in utero (IU) ZDV exposure among uninfected infants born to HIV+ women enrolled in ACTG 076 and 219
13. Hyperglycemia associated with protease inhibitors in HIV-infected patients
14. Protease inhibitor-associated hyperglycemia
15. Safety of zidovudine administered as post-exposure chemoprophylaxis to health care workers sustaining occupational exposures to HIV
16. Protease inhibitors may increase blood glucose in HIV patients
17. Tolerability, safety, and acceptability of zidovudine prophylaxis in health care workers
18. Management of occupational exposures to blood-borne viruses
19. Uberlegungen zur medikamentosen Postexpositionsprophylaxe nach beruflicher HIV-Exposition
20. An integrated protocol to manage health care workers exposed to bloodborne pathogens
21. Zidovudine toxicity in uninfected healthcare workers
22. The pharmacokinetics of 3TC administered to HIV-1 infected women (pre-partum, during labour and post-partum) and their offspring
23. HIV post-exposure prophylaxis
24. Abnormal fat accumulation in patients with HIV-1 infection
25. Safety of combined antiretroviral therapies with or without protease inhibitors in pregnant HIV-infected women and their offspring
26. Occupational risk of the acquired immunodeficiency syndrome among health care workers
27. Aggiornamento delle lineeguida per la chemioprofilassi con antiretrovirale dopo esposizione occupazionale ad HIV negli operatori sanitari
28. Antiviral effect of lamivudine alone and in combination with zidovudine in HIV-infected pregnant women
29. A review of protease inhibitors (P1) use in 89 pregnancies
30. AZT is a genomic transplacental carcinogen in animal models
31. Discontinuation of antiprotease inhibitor therapy due to drug toxicity: Study of a cohort of 309 patients
32. Follow-up of health care workers (HCWs) and prophylaxis after an occupational exposure to HIV: A no show
33. Antiretroviral prophylaxis of occupationally exposed health care workers at two large urban medical centers
34. Postexposure prophylaxis for human immunodeficiency virus: Frequency of initiation and completion of newly recommended regimen
35. Recent experience with post-exposure prophylaxis (PEP) with combination antiretrovirals for occupational exposure (OE) to HIV
36. Toxicity of antiretroviral agents
37. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood
38. Birth outcomes following zidovudine exposure in pregnant women: The Antiretroviral Pregnancy Registry